Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABvac40 in amnestic mild cognitive impairment or very mild Alzheimer's disease
2016-004352-30Phase 2Completed
- Sponsor
- Araclon Biotech
- Start
- Mar 2017
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ABvac40 in Alzheimer's disease (AD), amnestic mild cognitive impairment (MCI), sponsored by Araclon Biotech. Started Mar 2017; status: completed.
02
Drugs
ABvac40
03
Conditions
Alzheimer's disease (AD)amnestic mild cognitive impairment (MCI)
Beyond the preview
Go deeper on 2016-004352-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004352-30.